2‐oxoglutarate downregulates expression of vascular endothelial growth factor and erythropoietin through decreasing hypoxia‐inducible factor‐1α and inhibits angiogenesis
- 1 August 2006
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 209 (2) , 333-340
Abstract
In oxygenated cells, hypoxia‐inducible factor‐1 (HIF‐1) α subunits are rapidly degraded by a mechanism that involves ubiquitination by the von Hippel–Lindau tumor suppressor E3 ligase complex using 2‐oxoglutarate as a substrate. We examined the effect of 2‐oxoglutarate on the production of erythropoietin and vascular endothelial growth factor (VEGF). The expression of erythropoietin and VEGF protein were dose‐dependently downregulated in Hep3B cells by the addition of 2‐oxoglutarate. The promoter activity of VEGF‐luciferase was dose‐dependently downregulated by the addition of 2‐oxoglutarate. Gel mobility shift assays revealed that the addition of 2‐oxoglutarate dose‐dependently inhibited HIF‐1 binding activity, but did not affect GATA binding activity. Western blot analysis revealed that 2‐oxoglutarate dose‐dependently inhibited the HIF‐1α protein level in Hep3B cells in hypoxic conditions. However, MG132 (the proteasome inhibitor) rescued the inhibition of HIF‐1α protein expression by 2‐oxoglutarate. Furthermore, under hypoxic conditions, 2‐oxoglutarate dose‐dependently inhibited tube formation in in vitro angiogenesis assays. These results indicate that 2‐oxoglutarate treatment may be useful for the inhibition of angiogenesis. J. Cell. Physiol. 209: 333–340, 2006.Keywords
This publication has 43 references indexed in Scilit:
- The role of iron and 2-oxoglutarate oxygenases in signallingBiochemical Society Transactions, 2003
- Intracellular localisation of human HIF-1α hydroxylases:implications for oxygen sensingJournal of Cell Science, 2003
- Oxygen-Dependent Ubiquitination and Degradation of Hypoxia-Inducible Factor Requires Nuclear-Cytoplasmic Trafficking of the von Hippel-Lindau Tumor Suppressor ProteinMolecular and Cellular Biology, 2002
- Gene transfer of antisense hypoxia inducible factor-1 α enhances the therapeutic efficacy of cancer immunotherapyGene Therapy, 2001
- Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1αGenes & Development, 1998
- Activation of Hypoxia-inducible Factor-1; Definition of Regulatory Domains within the α SubunitJournal of Biological Chemistry, 1997
- Molecular Biology of the Coronary Vascular and Myocardial Responses to IschemiaJournal of Cardiovascular Pharmacology, 1992
- Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesisNature, 1992
- Novel inhibitors of prolyl 4-hydroxylase. 3. Inhibition by the substrate analog N-oxaloglycine and its derivativesJournal of Medicinal Chemistry, 1992
- Coronary collateral recruitment: Functional significance and relation to rate of vessel closureAmerican Heart Journal, 1991